nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—HTR2A—Gilles de la Tourette syndrome	0.951	1	CbGaD
Fluoxetine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00824	0.203	CbGeAlD
Fluoxetine—HTR2A—autonomic nervous system—Gilles de la Tourette syndrome	0.00495	0.122	CbGeAlD
Fluoxetine—Duloxetine—SLC6A3—Gilles de la Tourette syndrome	0.00315	0.417	CrCbGaD
Fluoxetine—Duloxetine—HTR2A—Gilles de la Tourette syndrome	0.00181	0.24	CrCbGaD
Fluoxetine—Atomoxetine—SLC6A3—Gilles de la Tourette syndrome	0.00165	0.218	CrCbGaD
Fluoxetine—HTR2C—midbrain—Gilles de la Tourette syndrome	0.00152	0.0375	CbGeAlD
Fluoxetine—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00144	0.0356	CbGeAlD
Fluoxetine—SIGMAR1—midbrain—Gilles de la Tourette syndrome	0.00143	0.0353	CbGeAlD
Fluoxetine—ORM1—nervous system—Gilles de la Tourette syndrome	0.00139	0.0343	CbGeAlD
Fluoxetine—ORM1—central nervous system—Gilles de la Tourette syndrome	0.00134	0.033	CbGeAlD
Fluoxetine—HTR2C—nervous system—Gilles de la Tourette syndrome	0.00125	0.0308	CbGeAlD
Fluoxetine—HTR2C—central nervous system—Gilles de la Tourette syndrome	0.0012	0.0297	CbGeAlD
Fluoxetine—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.00118	0.0292	CbGeAlD
Fluoxetine—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.00114	0.0281	CbGeAlD
Fluoxetine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.00104	0.0257	CbGeAlD
Fluoxetine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.001	0.0248	CbGeAlD
Fluoxetine—HTR2C—brain—Gilles de la Tourette syndrome	0.000954	0.0236	CbGeAlD
Fluoxetine—Atomoxetine—HTR2A—Gilles de la Tourette syndrome	0.000947	0.125	CrCbGaD
Fluoxetine—ALB—brain—Gilles de la Tourette syndrome	0.000931	0.023	CbGeAlD
Fluoxetine—SLC6A4—brain—Gilles de la Tourette syndrome	0.000905	0.0223	CbGeAlD
Fluoxetine—SIGMAR1—brain—Gilles de la Tourette syndrome	0.000899	0.0222	CbGeAlD
Fluoxetine—SLC6A2—brain—Gilles de la Tourette syndrome	0.000796	0.0197	CbGeAlD
Fluoxetine—CYP2B6—nervous system—Gilles de la Tourette syndrome	0.000768	0.019	CbGeAlD
Fluoxetine—HTR2A—midbrain—Gilles de la Tourette syndrome	0.000762	0.0188	CbGeAlD
Fluoxetine—CYP2B6—central nervous system—Gilles de la Tourette syndrome	0.000739	0.0183	CbGeAlD
Fluoxetine—HTR2A—nervous system—Gilles de la Tourette syndrome	0.000626	0.0155	CbGeAlD
Fluoxetine—HTR2A—central nervous system—Gilles de la Tourette syndrome	0.000603	0.0149	CbGeAlD
Fluoxetine—CYP2B6—brain—Gilles de la Tourette syndrome	0.000587	0.0145	CbGeAlD
Fluoxetine—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00058	0.0143	CbGeAlD
Fluoxetine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000571	0.0141	CbGeAlD
Fluoxetine—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.000558	0.0138	CbGeAlD
Fluoxetine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000549	0.0136	CbGeAlD
Fluoxetine—ABCB1—midbrain—Gilles de la Tourette syndrome	0.000499	0.0123	CbGeAlD
Fluoxetine—HTR2A—brain—Gilles de la Tourette syndrome	0.000479	0.0118	CbGeAlD
Fluoxetine—CYP2D6—brain—Gilles de la Tourette syndrome	0.000436	0.0108	CbGeAlD
Fluoxetine—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00041	0.0101	CbGeAlD
Fluoxetine—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.000395	0.00976	CbGeAlD
Fluoxetine—ABCB1—brain—Gilles de la Tourette syndrome	0.000314	0.00775	CbGeAlD
Fluoxetine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	7.31e-05	0.0596	CbGpPWpGaD
Fluoxetine—HTR2C—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	5.86e-05	0.0478	CbGpPWpGaD
Fluoxetine—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	5.6e-05	0.0457	CbGpPWpGaD
Fluoxetine—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	5.07e-05	0.0414	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	4.83e-05	0.0394	CbGpPWpGaD
Fluoxetine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	4.82e-05	0.0393	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	4.19e-05	0.0342	CbGpPWpGaD
Fluoxetine—HTR2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	4.12e-05	0.0336	CbGpPWpGaD
Fluoxetine—HTR2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	4e-05	0.0326	CbGpPWpGaD
Fluoxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	3.89e-05	0.0317	CbGpPWpGaD
Fluoxetine—HTR2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	3.72e-05	0.0304	CbGpPWpGaD
Fluoxetine—HTR2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	3.58e-05	0.0292	CbGpPWpGaD
Fluoxetine—HTR2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	3.47e-05	0.0283	CbGpPWpGaD
Fluoxetine—HTR2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	3.46e-05	0.0282	CbGpPWpGaD
Fluoxetine—HTR2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	3.36e-05	0.0274	CbGpPWpGaD
Fluoxetine—HTR2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	3.23e-05	0.0264	CbGpPWpGaD
Fluoxetine—HTR2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	3.13e-05	0.0255	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	3.01e-05	0.0245	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	2.92e-05	0.0238	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	2.72e-05	0.0222	CbGpPWpGaD
Fluoxetine—HTR2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	2.61e-05	0.0213	CbGpPWpGaD
Fluoxetine—HTR2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	2.19e-05	0.0179	CbGpPWpGaD
Fluoxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	1.98e-05	0.0162	CbGpPWpGaD
Fluoxetine—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	1.66e-05	0.0136	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	1.59e-05	0.013	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	1.54e-05	0.0126	CbGpPWpGaD
Fluoxetine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	1.43e-05	0.0117	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	1.4e-05	0.0114	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	1.36e-05	0.0111	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	1.27e-05	0.0103	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	1.09e-05	0.00886	CbGpPWpGaD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	9.02e-06	0.00735	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	7.95e-06	0.00648	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	7.71e-06	0.00629	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	7.19e-06	0.00586	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	6.9e-06	0.00563	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	6.81e-06	0.00555	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	6.7e-06	0.00546	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	6.61e-06	0.00539	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	6.51e-06	0.00531	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	6.24e-06	0.00509	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	6.16e-06	0.00502	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	5.91e-06	0.00482	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	5.82e-06	0.00475	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	5.74e-06	0.00468	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	5.35e-06	0.00436	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	5.18e-06	0.00423	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	5.03e-06	0.0041	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	5.03e-06	0.0041	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	4.69e-06	0.00382	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	4.58e-06	0.00374	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	4.53e-06	0.0037	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	4.5e-06	0.00367	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	4.37e-06	0.00356	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	4.31e-06	0.00352	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	4.07e-06	0.00332	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—HDC—Gilles de la Tourette syndrome	3.68e-06	0.003	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—HDC—Gilles de la Tourette syndrome	3.6e-06	0.00293	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	3.28e-06	0.00268	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—HDC—Gilles de la Tourette syndrome	3.1e-06	0.00253	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	2.93e-06	0.00239	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	2.84e-06	0.00232	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	2.78e-06	0.00227	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	2.72e-06	0.00221	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	2.66e-06	0.00217	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	2.65e-06	0.00216	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	2.58e-06	0.00211	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	2.56e-06	0.00209	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	2.54e-06	0.00207	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	2.54e-06	0.00207	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	2.47e-06	0.00201	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	2.41e-06	0.00196	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	2.31e-06	0.00188	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	2.3e-06	0.00188	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	2.3e-06	0.00188	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	2.24e-06	0.00183	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	2.17e-06	0.00177	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	2.09e-06	0.0017	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	2.02e-06	0.00165	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	1.86e-06	0.00151	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	1.68e-06	0.00137	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	1.67e-06	0.00136	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.57e-06	0.00128	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.53e-06	0.00124	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.42e-06	0.00116	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.36e-06	0.00111	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.32e-06	0.00108	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.23e-06	0.00101	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.95e-07	0.000812	CbGpPWpGaD
